Company Description
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products.
Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research.
It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD.
It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product.
Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 1956 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 122,000 |
| CEO | Marc Casper |
Contact Details
Address: 168 Third Avenue Waltham, Massachusetts 02451 United States | |
| Phone | 781 622 1000 |
| Website | thermofisher.com |
Stock Details
| Ticker Symbol | TMO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000097745 |
| CUSIP Number | 883556102 |
| ISIN Number | US8835561023 |
| Employer ID | 04-2209186 |
| SIC Code | 3829 |
Key Executives
| Name | Position |
|---|---|
| Marc N. Casper | Chairman, President and Chief Executive Officer |
| Stephen Williamson | Senior Vice President and Chief Financial Officer |
| Michel Lagarde | Executive Vice President and Chief Operating Officer |
| Lisa P. Britt | Chief Human Resources Officer and Senior Vice President |
| Gianluca Pettiti | Executive Vice President |
| Joseph R. Holmes | Vice President and Chief Accounting Officer |
| Ryan J. Snyder | Senior Vice President and Chief Information Officer |
| Dr. Karen E. Nelson Ph.D. | Chief Scientific Officer |
| Rafael Tejada | Vice President of Investor Relations |
| Michael A. Boxer Esq. | Senior Vice President and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 8, 2024 | 144 | Filing |
| Nov 7, 2024 | 144 | Filing |
| Nov 6, 2024 | 144 | Filing |
| Nov 1, 2024 | 144 | Filing |
| Nov 1, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 144 | Filing |
| Oct 30, 2024 | 144 | Filing |
| Oct 29, 2024 | 144 | Filing |
| Oct 28, 2024 | 144 | Filing |
| Oct 25, 2024 | 144 | Filing |